anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A cosmetic composition comprising a compound having a melting peak with a mid-height width of 10 deg.C or less and an amorphous film-forming polymer capable of forming a water-soluble film in a pharmacologically acceptable medium is provided. It improves an eyelash curling, exhibits excellent cosmetic characteristics and can be used by the combination with a heating device such as a heating brush, in which the device can be applied to the eyelash before, during or after coating the eyelash with the composition. CONSTITUTION: The cosmetic composition consists of: (i)1 to 60% by weight of at least one first compound giving a thermal profile having a melting peak of a mid-height width Lf of 10deg.C or less to the composition; and (ii) at least one amorphous film-forming polymer which present in a amount at least equal to the amount of the first compound in a pharmacologically acceptable medium. The first compound is selected from wax, a semi-crystalline polymer, oil thickened with a structuring agent and a mixture thereof. The semi-crystalline polymer is selected from at least one monomer and copolymers formed by polymerization of at least one fluorinated or not fluorinated C1-10 monocarboxylic acid ester or amide of the formula 1. In formula, R1 is H or CH3, R is fluorinated or not fluorinated C1-10 alkyl, X is O, NH or NR2(R2 is fluorinated or not fluorinated C1-10 alkyl).
An agent to stimulate the natural defenses of a human and/or animal i.e. mammal body against infection comprising a microbial antigen-antitoxin combination, is new. The agent can be a powder, ointment, spray, liquid for oral administration, tablets, vaginal or anal suppositories. ACTIVITY : Antimicrobial. No biological data given. MECHANISM OF ACTION : None given.
PURPOSE: The purpose of this study was to develop and validate prediction model for myopic macular degeneration (MMD) progression in patients with high myopia.
METHODS: The Zhongshan High Myopia Cohort for model development included 660 patients aged 7 to 70 years with a bilateral sphere of ≤-6.00 diopters (D). Two hundred twelve participants with an axial length (AL) ≥25.5 mm from the Chinese Ocular Imaging Project were used for external validation. Thirty-four clinical variables, including demographics, lifestyle, myopia history, and swept source optical coherence tomography data, were analyzed. Sequential forward selection was used for predictor selection, and binary classification models were created using five machine learning algorithms to forecast the risk of MMD progression over 10 years.
RESULTS: Over a median follow-up of 10.9 years, 133 patients (20.2%) showed MMD progression in the development cohort. Among them, 69 (51.9%) developed newly-onset MMD, 11 (8.3%) developed patchy atrophy from diffuse atrophy, 54 (40.6%) showed an enlargement of lesions, and 9 (6.8%) developed plus signs. Top six predictors for MMD progression included thinner subfoveal choroidal thickness, longer AL, worse best-corrected visual acuity, older age, female gender, and shallower anterior chamber depth. The eXtreme Gradient Boosting algorithm yielded the best discriminative performance (area under the receiver operating characteristic curve [AUROC] = 0.87 ± 0.02) with good calibration in the training cohort. In a less myopic external validation group (median -5.38 D), 48 patients (22.6%) developed MMD progression over 4 years, with the model's AUROC validated at 0.80 ± 0.008.
CONCLUSIONS: Machine learning model effectively predicts MMD progression a decade ahead using clinical and imaging indicators. This tool shows promise for identifying "at-risk" high myopes for timely intervention and vision protection.
Patients \>18 years of age with an america society of anesthesiologist classification of I or II who are scheduled to undergo elective robot assisted laparoscopic radical prostatectomy are included. The exclusion criteria are a history of neuromuscular, renal, or hepatic disease, known allergy to rocuronium or sugammadex. Patients are randomized to either the moderate or deep neuromuscular blockade group using Random Allocation Software (version 1.0). In the operating room, routine monitoring is performed, including electrocardiography, non-invasive arterial pressure measurements, and pulse oximetry. Additionally, acceleromyography are applied to monitor the response of the adductor pollicis muscle. After the induction of anesthesia with propofol and before rocuronium administration, the TOF-Watch-SX is calibrated and stabilised, and a series of train-of-four (TOF) measurements are documented every 1 min. Next, intravenous rocuronium at 0.6 mg/kg was administered, and tracheal intubation was performed after confirmation of relaxation. Anesthesia is maintained with desflurane and target-controlled infusion of remifentanil while monitoring the bispectral index. Intravenous rocuronium (5-10 mg) is used to maintain moderate (TOF count of 1 or 2) or deep (post-tetanic count \[PTC\] of 1 or 2) neuromuscular blockade. Peak inspiratory pressure and plateau pressure are recorded until 1 hour after pneumoperitoneum. At the end of the operation, the surgeon rated the surgical condition on a 5-point scale. Patients are reversed with intravenous sugammadex at 2 or 4 mg/kg. Postoperative pulmonary complications (SpO2 \<100%, RR\<8, atelectasis) are assessed and recorded.
The present invention provides compositions for the lysis and killing of microbes in general, and in particular provides oral compositions for the lysis and killing oral bacteria. The compositions of the present invention include a humectant such as glycerol, sorbitol or comparable compounds and provide an in-mouth concentration of such substances from about 20% to about 80% weight/volume in dentifrice preparations, in particular mouthrinses. These compositions further comprises (a) bicarbonate ion at about 0.5% to about 2% wt./vol. and if desired, thiocyanate, chloride or fluoride ion at about 0.5% to about 2% wt./vol. (b) sodium lauroyl sarcosinate or other anionic detergents from about 0.05% to about 1% wt./vol. and (c) Tween 20 or other non-ionic detergents or structurally similar compounds from about 0.01% to about 3% vol./vol. In addition, alcohol may be added up to a level of 15% vol./vol. along with appropriate sweetening and flavoring agents. Water is then added to 100%. The compositions may be introduced in a manner and vehicle suitable for oral cavity administration. This invention also relates to a method of using such compositions for treating and inhibiting dental caries, dental plaque and gingivitis, oral malodor and periodontopathic conditions in mammals, particularly humans, in need of anti-caries, anti-plaque, anti-gingivitis, anti-malodor or anti-periodontopathic therapy. The compositions of the present invention are conventionally formulated into mouthrinses (mouth washes) and the commonly utilized dentifrice treatment agents.
The invention discloses tea-flavored white spirit, which is prepared from the following raw materials (by weight): 500-510 parts of rice, 18-19 parts of tea, 10-11 parts of wheatberry, 2-3 parts of cornua cervi pantotrichum, 1-2 parts of rosa rugosa, 3-4 parts of rhodiola, 2-3 parts of ganoderma lucidum, 5-6 parts of baking soda, 0.25-0.3 part of saccharifying enzyme, 0.1-0.2 part of amylase, a proper amount of lactic acid, 5-6 parts of distiller's yeast, 0.8-0.9 part of chitosan, and 1-1.2 parts of carrageenan. After roasted and puffed, the raw material rice has a porous and loose structure, which is beneficial to saccharifying enzyme catalyzed hydrolysis. The introduced superheated steam has large heat transfer coefficient, thus accelerating heating rate of rice. After baking soda is dissolved in water, hydroxide ions are ionized out of the solution. Therefore, association among water molecules is weakened, degree of freedom of water molecules is increased, and water molecules are easy to enter rice starch molecules to swell rice and enhance degree of gelatinization. With the addition of chitosan and carrageenan, gastric acid which is produced under stimulation of alcohol can be neutralized, thus reducing stimulus. In addition, the product is anti-aging.
PURPOSE:To form a printed rough surface portion having excellent durability and permanently not changed.deteriorated on the subject coating layer by disposing the smooth coating layer of a thermoplastic resin on a substrate having a printing layer thereon and thermally melting the printing portion. CONSTITUTION:For example, a smooth coating layer 4 comprising a thermoplastic resin (e.g. a polyester, polyethylene or polyvinyl chloride) is disposed on a substrate 2 (e.g. paper or synthetic resin) having a printed layer 3 to form a heat-sensitive printing sheet 1. Heat is added to the desired portion of the sheet 1 with a heated head to melt the coating layer 4 for the formation of a rough surface portion 6. A printing mechanism employing a conventional heat-generating head can be used as such.
PURPOSE:To prepare immune globulin having an excellent quality in a short time in a high yield while reducing the load of waste solution treatment, by treating a defatted colostrum or colostrum whey with an ultrafiltration membrane having a fractionation mol.wt. range. CONSTITUTION:A defatted colostrum or colostrum whey is treated with an ultrafiltration membrane having a fractionation mol.wt. of 50000-150000, preferably 100000, to remove not only low molecules in the colostrum whey but also most of milk-originated proteins such as alpha-lactoalbumin, beta-lactoglobulin and serum albumin, thereby preparing an immune globulin concentration solution in a globulin loss state of <=1%. The concentration solution is lyophilized or spray-dried to prepare while scaly-yellowish white powder having a very light bulk specific gravity. The finely ground powder is mixed with a hydrophilic compound (e.g. a saccharide or sugar alcohol), sprayed with a small amount of water, sufficiently kneaded and subsequently granulated to provide the objective medicine highly improved in the dispersibility and solubility in digestive tracts and effectively exhibiting antiviral activities thereof.
Bone metastases are common in patients with advanced breast and prostate cancers. Skeletal metastases can be associated with reduced Quality of Life (QoL), pain and skeletal-related events (SREs) (defined as pathological fractures, surgery/radiotherapy to bone, spinal cord compression and hypercalcaemia). Maintaining QoL while avoiding or delaying SREs are the main goals of therapy. Patients therefore receive bone-targeted agents (e.g. pamidronate, zoledronate and denosumab) which are typically given every 4 weeks. However, this 4 week dosing is based on convenience so the treatment could be given concurrently with chemotherapy. The half-life of these drugs in the bone is many months or even years. Hence studies have been performed evaluating 12-weekly therapy. These have confirmed similar palliative outcomes in the 4 vs 12-weekly groups for both breast and prostate cancer patients. However, there remains clinical equipoise about which dosing interval physicians prescribe. The current trial will compare these two schedules of bone-targeting agents (12- vs. 4-weekly) to evaluate quality of life, pain and skeletal events within the Canadian Health Care System. This study will use an "integrated consent model" that involves "oral consent" rather than a written informed consent writing process as the study is comparing standard schedules and not a new administration schedule.
The 33% and 67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks; 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks).
PURPOSE: This multicenter retrospective study focuses on understanding the incidence, causative bacteria, and risk factors for Periprosthetic Joint Infection (PJI) following hemiarthroplasty in elderly patients with displaced femoral neck fractures (FNF).
METHODS: From 2016 to 2020, 1,619 patients were diagnosed with displaced FNFs and treated surgically across 11 centers. After exclusions, 1,438 patients (399 men and 1,039 women) were included in the study, averaging 82.1 years in age and 20.2 kg/m² in BMI, observed over 25.7 months on average. Data on demographics, medical history, surgical details, and complications were described.
RESULTS: PJI occurred in 20 of the 1438 patients (1.4%). The causative organism was methicillin-susceptible Staphylococcus aureus in 6 patients and methicillin-resistant S. aureus in 6 patients. In patients' backgrounds, the average age was slightly higher in the non-PJI group (82.1 years) compared to the PJI group (80.4 years). There was a higher percentage of males in the PJI group (45%) than in the non-PJI group (27.5%). Drug history showed that the prevalence of anticoagulant use in the PJI group was 25%. Peripheral vascular disease and diabetes mellitus were more prevalent in the PJI group. Most patients in both groups were independent in daily activities. The blood transfusion rate was significantly higher in the PJI group (50%) than in the non-PJI group (23.8%). Notably, the incidence of hematoma was higher in the PJI group (40%).
CONCLUSION: This multicenter retrospective study demonstrates a low incidence (1.4%) of PJI in elderly patients undergoing hemiarthroplasty for FNF, primarily due to Staphylococcus aureus. Increased usage of antiplatelets and anticoagulants, as well as comorbidities related to atherosclerosis, like peripheral vascular disease and diabetes mellitus, were observed in patients with PJI. Additionally, these patients experienced higher rates of blood transfusion and postoperative hematomas, highlighting the need for careful management. It should be noted, however, that this finding is a conclusion limited by study design issues, including the retrospective design, small PJI sample size, and variability in treatment approaches.
INTRODUCTION: Buffalo/Mna rats spontaneously develop nephrotic syndrome (NS) which recurs after renal transplantation. The immunosuppressive drug LF15-0195 can promote regression of the initial and post-transplantation nephropathy via induction of regulatory T cells. We investigate if this drug has an additional effect on the expression and localization of podocyte specific proteins.
METHODS: Buffalo/Mna kidney samples were collected before and after the occurrence of proteinuria, and after the remission of proteinuria induced by LF15-0195 treatment and compared by quantitative RT-PCR, Western blot, electron, and confocal microscopy to kidney samples of age-matched healthy rats. Cytoskeleton changes were assessed in culture by stress fibers induction by TNFα.
RESULTS: We observed, by electron microscopy, a restoration of foot process architecture in the LF15-0195-treated Buff/Mna kidneys, consistent with proteinuria remission. Nephrin, podocin, CD2AP, and α-actinin-4 mRNA levels remained low during the active disease in the Buff/Mna, in comparison with healthy rats which increase, while podocalyxin and synaptopodin transcripts were elevated before the occurrence of the disease but did not differ from healthy animals after. No difference in the mRNA and protein expression between the untreated and the LF15-0195-treated proteinuric Buff/Mna were seen for these 6 proteins. No changes were observed by confocal microscopy in the protein distribution at a cellular level, but a more homogenous distribution similar to healthy rats, was observed within the glomeruli of LF15-0195-treated rats. In addition, LF15-0195 could partially restore actin cytoskeleton of endothelial cells in TNFα-induced-cell stress experiment.
CONCLUSION: The effect of LF15-0195 treatment appears to be mediated by 2 mechanisms: an immunomodulatory effect via regulatory T cells induction, described in our previous work and which can act on immune cell involved in the disease pathogenesis, and an effect on the restoration of podocyte cytoskeleton, independent of expression levels of the proteins involved in the slit diaphragm and podocyte function, showed in this article.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely ophthalmology, and can be used for prevention and treatment of postoperative corneal oedemas in complicated cataract surgery. For this purpose, at the final stage of cataract phacoemulsification, washout of a viscoelastic is followed by introduction of ozonised physiologic saline 0,5 ml in the concentration of 2 mg/l. Besides, the solution 0.5 ml is introduced subconjunctivally. Besides, the patients with persistent postoperative corneal oedema requires additional postoperative subconjunctival introduction in the same dosage to remove oedema. ^ EFFECT: while being simple and accessible, the method ensures more efficient surgery, including due to prevention of postoperative corneal oedemas in complicated cataract surgery, including black cataracts, considerably reducing a length of postoperative treatment and rehabilitation of such patients.
Exercise-induced hypoxaemia (EIA) is very common in individuals with ILD, due to progressive lung fibrosis which results in impaired gas exchange. It is common for people with EIA to be prescribed ambulatory oxygen, in order to normalize oxyhaemoglobin saturation, improve oxygen delivery to the tissues and relieve breathlessness during daily activities.

Ambulatory oxygen is traditionally delivered via a refillable portable oxygen cylinder containing compressed gaseous oxygen. More recently, portable oxygen concentrators (POCs) have emerged as a solution to the problem of finite cylinder life and to improve portability. Because a concentrator is constantly extracting oxygen from air, oxygen supply can continue as long as the battery is charged. This is typically around eight hours, but POCs can be recharged from an AC or DC power source. Portable oxygen concentrators usually weigh around 3.5kg, which is significantly lighter than oxygen cylinders, and are much easier to maneuver. However, there are some theoretical disadvantages to POCs. Like all concentrators, they do not deliver 100% oxygen. Concentrations typically range from 85-95%, depending on the flow rate. Differences in pulse timing and peak pulse flow between POCs may affect the fraction of inspired oxygen (FiO2) that is delivered. However, the clinical implications of these differences have not been documented.

The aim of this study is to compare the effects of ambulatory oxygen delivered during exercise using the EverGo POC to ambulatory oxygen delivered with a standard portable cylinder in individuals with ILD. We hypothesise that oxyhaemoglobin saturation during exercise will be significantly higher when using a portable cylinder, but this difference will not be clinically important.
PROBLEM TO BE SOLVED: To obtain the subject function improver effectively acting upon unidentified clinical syndrome symptoms such as systemic feebleness, fatigue, numbness of limb, shoulder stiffness and fatigue of eyes by combinedly using γ-oryzanol with a central nerve stimulator. SOLUTION: This function improver is obtained by combinedly using (A) γ-oryzanol with (B) a central nerve stimulator as active ingredients. The ingredient A is a generic term of agents included in nonsaponified materials in rice bran oil, having maximum absorbance at 231, 291 and 315 μm and a mixture of two or more kinds of unsaturated terpene alcohol-based ferulic acid esters. The ingredient B is preferably at least one selected from spicy ingredients of (i) ginger, (ii) capsicum and (iii) pepper and (iv) caffeine. This function improver is preferably used as a preparation for oral administration. The daily effective dose is preferably 1-500 mg ingredient A, 5-300 mg ingredient iv, 1 mg-50 g ingredient i, 0.1 mg-2 g ingredient ii and 0.1 mg-2 g ingredient iii.
BACKGROUND: Inflammation is a major contributing factor in myocardial ischemia/reperfusion (I/R) injury, and targeting macrophage inflammation is an effective strategy for myocardial I/R therapy. Though remimazolam is approved for sedation, induction, and the maintenance of general anesthesia in cardiac surgery, its effect on cardiac function during the perioperative period has not been reported. Therefore, this research aimed to explore the impact of remimazolam on inflammation during myocardial ischemia/reperfusion (I/R) injury.
METHODS: An in vivo myocardial I/R mice model and an in vitro macrophage inflammation model were used to confirm remimazolam's cardiac protective effect. In vivo, we used echocardiography, hematoxylin and eosin (HE), and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining to determine remimazolam's therapeutic effects on myocardial I/R injury and inflammation. In vitro, we employed enzyme-linked immunosorbent assay (ELISA), Western blot, Real-time Quantitative PCR (qPCR), flow cytometry, and immunofluorescence staining to assess inflammatory responses, especially remimazolam's effects on macrophage polarization after I/R. Furthermore, molecular docking was used to identify its potential binding targets on the inflammatory pathway to explore the mechanism of remimazolam.
RESULTS: Remimazolam exhibited significant anti-myocardial I/R injury activity by inhibiting macrophage-mediated inflammation to reduce myocardial infarction, enhancing cardiac function. In addition, macrophage depletion counteracted improved cardiac function by remimazolam treatment. Mechanistically, the activated NF-ĸB signaling pathway and phosphorylation of p50 and p65 were repressed for anti-inflammatory effect. Consistently, two binding sites on p50 and p65 were identified by molecular docking to affect their phosphorylation of the Ser, Arg, Asp, and His residues, thus regulating NF-κB pathway activity.
CONCLUSION: Our results unveil the therapeutic potential of remimazolam against myocardial I/R injury by inhibiting macrophages polarizing into the M1 type, alleviating inflammation.
Idiopathic pulmonary fibrosis (IPF) is characterized by a progressive decline in lung function, worsening quality of life, and high mortality. However, the rate and pattern of progression of IPF are variable. Real-world studies, which include a broader population of patients than clinical trials and collect data over longer periods, have provided important information on the clinical course of IPF and further insights into the efficacy and safety of antifibrotic therapies. They also highlight the worsening of patients' quality of life as lung function is lost, the high frequency of hospitalizations, and the impact of acute exacerbations on mortality in patients with IPF. Data from patient registries and analyses of claims data suggest that antifibrotic therapy is more likely to be used in patients who have worse lung function and that its use is associated with an improvement in life expectancy. The safety profile of antifibrotic therapies in real-world populations is consistent with that observed in clinical trials. Further real-world studies are needed to improve understanding of the course and impact of IPF in specific groups of patients and how the care provided to these patients might be improved.